EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study

Sho Sato, Takashi Ssuzuki, Takashi Chinen, Hironori Yamaguchi, Yusuke Suzuki, Nobukazu Hokamura, Zenichiro Saze, Koji Kono, Keita Takahashi, Fumiaki Yano, Chikara Kunisaki, Takashi Kosaka und 5 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02532-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Sho Sato und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yokohama City University Gastroenterological Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsImmune Checkpoint InhibitorsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overAdultProgression-Free SurvivalC-Reactive Protein

Stichwörter der Autor:innen

Antineoplastic agentsClinical malignantEsophageal neoplasmsImmunotherapy

Substanzen

Immune Checkpoint InhibitorsC-Reactive Protein

Autor:innen und Institutionen

  • Department of Surgery, Yokohama City University Gastroenterological Center, Yokohama, Japan.
  • Department of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
  • Department of Clinical Oncology, Jichi Medical University Hospital, Tochigi, Japan.
  • Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
  • Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan.
  • Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.

Zitieren

APA

Sato, S., Ssuzuki, T., Chinen, T., Yamaguchi, H., Suzuki, Y., Hokamura, N., Saze, Z., Kono, K., Takahashi, K., Yano, F., Kunisaki, C., Kosaka, T., Endo, I., Ichikawa, Y., Miyawaki, Y., Sato, H., & Shimada, H. (2024). The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02532-0

Vancouver

Sato S, Ssuzuki T, Chinen T, Yamaguchi H, Suzuki Y, Hokamura N, et al. The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02532-0

BibTeX
@article{Sato2024,
  author = {Sato, Sho and Ssuzuki, Takashi and Chinen, Takashi and Yamaguchi, Hironori and Suzuki, Yusuke and Hokamura, Nobukazu and Saze, Zenichiro and Kono, Koji and Takahashi, Keita and Yano, Fumiaki and Kunisaki, Chikara and Kosaka, Takashi and Endo, Itaru and Ichikawa, Yasushi and Miyawaki, Yutaka and Sato, Hiroshi and Shimada, Hideaki},
  title = {The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02532-0}
}
Kostenlos starten →